EverCommerce has fallen 20% in a week and 36% over the past month, yet the borrowing market remains structurally starved of supply — an unusual setup where the stock keeps dropping without any obvious short-squeeze pressure to arrest it.
The lending picture is the clearest signal here. Availability has tightened dramatically over the summer. Through mid-to-late August, the borrow pool was effectively fully exhausted on multiple days — availability touching zero on August 18 and several surrounding sessions. It has since eased to around 6%, but that still leaves fewer than one share available for every fifteen already lent out, well inside "very tight" territory. The cost to borrow reflects that scarcity: fees are running near 42% annualised, roughly in line with where they were a month ago but meaningfully below the 60% peak reached in early August. Despite all this, short interest is barely 1% of the free float — roughly 1.8 million shares — and it has barely moved over the past month. The borrow is tight and expensive not because shorts are crowding in, but because the float itself is highly concentrated and the available lending pool is structurally small.
That ownership structure is the key context. PSG Equity holds 48% of shares and Silver Lake a further 38%. Together they account for over 86% of the company, leaving a tiny tradeable float. Director Eric Remer, disclosed on Schedule 13G as holding around 7.5% of the class, trimmed roughly 9,400 shares in early September in open-market sales — modest in absolute dollar terms at around $75,000 but notable given the stock's trajectory. The President Matthew Feierstein and CFO Ryan Siurek also appear in recent filings, but those transactions are coded as tax-withholding ("F") on vesting RSUs, not discretionary sales, and carry far less signal. Net insider activity over the trailing 90 days runs to around $5.9 million in net selling, though most of that is compensation mechanics rather than conviction.
Options traders have turned decidedly less defensive than they were a month ago — and that itself is striking. The put/call ratio has collapsed from above 13 in late August to 1.76 now, nearly 1.7 standard deviations below its 20-day average of 8.0. That's a dramatic unwind of the heavy put-buying that characterised August positioning. It could reflect puts rolling off after the stock repriced lower rather than any renewed bullish conviction, but the swing is large enough to notice.
Analysts are not covering themselves in glory here either. After the August 6 earnings print — which sent the stock down 11% on the day and 17% over the subsequent week — RBC Capital trimmed its target to $10 from $11 while holding at Sector Perform, and Barclays actually raised its target modestly to $10 from $8.50 while keeping an Underweight rating. That leaves the Street consensus mean target around $11, implying roughly 74% upside from current levels — though that figure should be read carefully, given the stock has now fallen well below where most of these targets were anchored. Goldman Sachs carries a Sell with an $8 target (set in March), which now looks prescient. Valuation multiples have compressed sharply: price-to-book has fallen by a third in 30 days to 1.6x, and the PE multiple has shed more than four turns to sit near 8.4x. The ORTEX short score is elevated at 94, consistent with the tight borrow and high structural short pressure relative to the float size, even if absolute short interest is low.
The next scheduled earnings event is November 6. The past two prints produced double-digit single-day declines, and the five-day move after both was worse still — down roughly 15-17% each time. With the stock already down more than 40% year-to-date and availability still well below 50%, the question heading into that print is whether the borrow market tightens further as the date approaches, or whether the continued price weakness creates enough turnover to loosen supply.
See the live data behind this article on ORTEX.
Open EVCM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
